What are alternative therapies to Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide) for COPD management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Alternative Therapies to Trimbow for COPD Management

For patients currently on Trimbow (triple therapy with ICS/LABA/LAMA), the most appropriate alternative depends on their exacerbation risk and symptom burden, with LAMA/LABA dual therapy being the preferred step-down option for most patients, or switching to an alternative triple therapy formulation if triple therapy remains indicated.

Clinical Decision Algorithm

Step 1: Determine if Triple Therapy is Still Indicated

Triple therapy should be continued (with an alternative formulation) if the patient has:

  • ≥2 moderate exacerbations OR ≥1 severe exacerbation (requiring hospitalization/ED visit) in the past year, AND
  • Moderate-to-high symptom burden (CAT ≥10 or mMRC ≥2), AND
  • Impaired lung function (FEV₁ <80% predicted) 1

Alternative triple therapy options include:

  • Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI)
  • Budesonide/glycopyrronium/formoterol (BUD/GLY/FOR) 2, 3

These formulations have demonstrated efficacy in reducing exacerbations and improving lung function, though direct head-to-head comparisons with Trimbow are limited 3.

Step 2: Consider Step-Down to Dual Therapy

LAMA/LABA dual therapy is the preferred alternative if:

  • Patient has ≤1 moderate exacerbation in the past year (low exacerbation risk), OR
  • Patient experiences ICS-related adverse effects (pneumonia, oral candidiasis), OR
  • Blood eosinophils are consistently low (<100 cells/μL)

The 2023 Canadian Thoracic Society guidelines strongly recommend LAMA/LABA over ICS/LABA for dual therapy because it provides additional lung function improvements with lower rates of adverse events, particularly pneumonia 1. The 2017 GOLD guidelines similarly prioritize LAMA/LABA for Group D patients (high symptoms, high exacerbation risk) over ICS/LABA combinations 4.

Available LAMA/LABA combinations include:

  • Glycopyrronium/formoterol (available as pMDI) 5
  • Umeclidinium/vilanterol
  • Tiotropium/olodaterol
  • Aclidinium/formoterol

Step 3: Alternative Pathways Based on Clinical Response

If patient remains on LAMA/LABA but develops breakthrough exacerbations:

  • Escalate back to triple therapy (LAMA/LABA/ICS), OR
  • Switch to ICS/LABA, then add LAMA if inadequate response 4

If patient continues triple therapy but still experiences exacerbations, consider adding:

  • Roflumilast (if FEV₁ <50% predicted with chronic bronchitis and ≥1 hospitalization for exacerbation in prior year)
  • Macrolide therapy in former smokers (azithromycin), though weigh risk of antimicrobial resistance 4

Key Considerations for Formulation Selection

Extrafine vs. Non-Extrafine Formulations

Trimbow uses an extrafine formulation that achieves higher peripheral (small airways) deposition compared to non-extrafine alternatives like FF/UMEC/VI 6. If small airways disease is a prominent feature, consider:

  • Beclometasone/formoterol (BDP/FF) dual therapy as extrafine formulation
  • Alternative extrafine triple therapy if available in your region

Device Considerations

Pressurized metered-dose inhalers (pMDIs):

  • Require coordination of actuation and inhalation
  • Can be used with spacer devices to improve delivery and reduce oropharyngeal deposition 7
  • Suitable for patients who can generate adequate inspiratory flow

Dry powder inhalers (DPIs):

  • Breath-actuated, eliminating coordination requirement
  • Require adequate inspiratory flow (may be problematic in severe COPD)
  • Some patients prefer DPI over pMDI

Critical Pitfalls to Avoid

  1. Do not use ICS/LABA as first-line dual therapy - LAMA/LABA is superior with lower pneumonia risk 1

  2. Do not continue triple therapy indefinitely without reassessing - If exacerbations are controlled and eosinophils are low, consider ICS withdrawal to reduce pneumonia risk 4

  3. Do not use LABA monotherapy - Always combine with LAMA and/or ICS 8

  4. Do not exceed recommended dosing - Formoterol should not exceed 40 mcg total daily dose (one vial twice daily for nebulized formulations) 8

  5. Ensure patients understand these are maintenance therapies - Short-acting bronchodilators (albuterol/salbutamol) should be available for acute symptom relief 8

Special Populations

Patients with asthma-COPD overlap features (bronchodilator reversibility, elevated eosinophils ≥300 cells/mm³):

  • Triple therapy demonstrates superior outcomes compared to dual therapy 2
  • ICS-containing regimens are particularly important in this population
  • Consider BUD/GLY/FOR as alternative, which showed benefits in this phenotype 2

Patients with cardiovascular disease:

  • Use caution with all beta-agonists (formoterol, vilanterol)
  • Monitor for tachycardia, arrhythmias, blood pressure changes 8
  • Consider LAMA monotherapy if dual/triple therapy causes cardiovascular symptoms

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.